China Resources Double-Crane Pharmaceutical's (SHA:600062) unit, China Resources Double-Crane Xiangzhong Pharmaceutical (Hunan), received a certificate of suitability from the European Union's drug regulator for its sodium valproate activity pharmaceutical ingredient, according to a Shanghai bourse filing on Thursday.
The drug is used to treat neurological and psychiatric disorders, primarily epilepsy and mania associated with bipolar disorder.